A Phase 3 interventional study of Ibuprofen 400 mg caplet in Patient Compliance, sponsored by Pfizer. Completed at 25 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-05-30.
Sponsored by Pfizer · Phase 3 and Interventional
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 240 studies in Patient Compliance with a site in United States — 9 open to participants now, 19 under way, 1 of them phase 3. Patient Compliance · United States.
Among the 240 studies in Patient Compliance with a site in United States, this one is the 22nd largest by enrollment of the 201 interventional ones that give a count, is one of 15 that started in 2014, is one of 9 in phase 3, and was the 136th registered.
752 studies on the registry are indexed under Patient Compliance; 72 are open to participants now.
Browse Patient Compliance studies →9 of the 240 studies in Patient Compliance with a site in United States are open now. Recruiting first, the newest first:
VA Office of Research and Development · Sites in United States
Ages 18+ · Healthy volunteers
VA Office of Research and Development · Sites in United States
Ages 18–90
HiDO Technologies · Sites in United States
Ages 65+
University of California, San Francisco · Sites in United States
Ages 60+
University of Georgia · Sites in United States
Ages 18–26 · Women only · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 45 Patient Compliance studies recruiting now, 25 (56%) set no upper age limit and 13 (29%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
240 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 14 · Phase 3 12 · Phase 4 10
First in 1993; this study’s year is marked. 15 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 738 is above the median of 116 across 527 interventional studies indexed under Patient Compliance.
Median enrollment 119 across the 201 interventional studies, 92 across the 37 observational. Of the 203 that completed or were terminated, 65 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 240 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Pfizer has 3 studies filed under Patient Compliance — fewer than ten, so there is no comparison to draw.
6 of the studies in Patient Compliance with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07520786University of GeorgiaChanges in 24-hour Activity Cycle Behaviors During a Time-Restricted Eating Intervention in College-Aged Women | 2026-11 |
| NCT04238949Children's Hospital of PhiladelphiaCommunity Health Workers in Pediatric Patients With Newly Diagnosed Type 1 Diabetes | 2027-01 |
| NCT05448560Georgetown UniversityA Multilevel Intervention to Improve Adherence to Childhood Cancer Survivorship | 2027-02-28 |
| NCT05157113University of California, San FranciscoEvaluating a Dropless Postoperative Regimen After Cataract Surgery in a Vulnerable, County-hospital Population | 2027-06-01 |
| NCT06591182BayCare Health SystemEffects of Social Determinants of Health on IV Iron Treatments | 2027-07 |
Add all 6 to your calendar (.ics) → With an account.
Among the 240 studies in Patient Compliance with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is an open label, multicenter, 30 day study designed to mimic an OTC like environment in which subjects will use the product after making a purchase decision about ibuprofen 400 mg caplets based only on their reading of the Drug Facts Label (DFL) and other information on the package.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: Ibuprofen 400 mg caplet
400 milligram (mg) caplet according to Drug Facts label
Percentage of Participants Taking Greater Than (>) 1200 Milligram (mg) (>3 Caplets) on no More Than 2 Use Days During the Study
Percentage of participants whose behavior was either correct or acceptable were considered to be compliant. The behavior was considered correct if participants took more than 1200 mg (\>3 caplets) on either 0, 1 or 2 use days (where a use day was defined as a calendar day starting at 12:01 AM in which a participant received at least one dose of study medication), based on their diary. The behavior was considered acceptable if a participant exceeded the labelled daily dosing directions of taking more than 3 caplets per day, under the advice of a healthcare professional, based on information from the end of study follow-up interview.
Time frame: Day 1 up to 30 days
Percentage of Participants Taking Greater Than (>) 400 mg (>1 Caplet) at a Time on no More Than 2 Dosing Occasions During the Study
Percentage of participants whose behavior was either correct or acceptable were considered to be compliant. The behavior was considered correct if the total number of dosing occasions (distinct usage date/time values from their diary) in which a participant received 2 or more caplets was 0, 1 or 2. The behavior was considered acceptable if a participant exceeded the labelled daily dosing directions of taking no more than 1 caplet per dose, under the advice of a healthcare professional, based on the end of study follow up interview.
Time frame: Day1 up to 30 days
| Milestone | Ibuprofen |
|---|---|
| Started | 738 |
| Completed | 635 |
| Not completed | 103 |
| Withdrew: Adverse event | 2 |
| Withdrew: Protocol violation | 68 |
| Withdrew: Lost to follow-up | 31 |
| Withdrew: Other | 1 |
| Withdrew: Withdrawal by subject | 1 |
Percentage of participants whose behavior was either correct or acceptable were considered to be compliant. The behavior was considered correct if participants took more than 1200 mg (\>3 caplets) on either 0, 1 or 2 use days (where a use day was defined as a calendar day starting at 12:01 AM in which a participant received at least one dose of study medication), based on their diary. The behavior was considered acceptable if a participant exceeded the labelled daily dosing directions of taking more than 3 caplets per day, under the advice of a healthcare professional, based on information from the end of study follow-up interview.
| percentage of participants | Ibuprofen |
|---|---|
| Percentage of Participants Taking Greater Than (>) 1200 Milligram (mg) (>3 Caplets) on no More Than 2 Use Days During the Study | 95.2 (93.6 to 96.8) |
Percentage of participants whose behavior was either correct or acceptable were considered to be compliant. The behavior was considered correct if the total number of dosing occasions (distinct usage date/time values from their diary) in which a participant received 2 or more caplets was 0, 1 or 2. The behavior was considered acceptable if a participant exceeded the labelled daily dosing directions of taking no more than 1 caplet per dose, under the advice of a healthcare professional, based on the end of study follow up interview.
| percentage of participants | Ibuprofen |
|---|---|
| Percentage of Participants Taking Greater Than (>) 400 mg (>1 Caplet) at a Time on no More Than 2 Dosing Occasions During the Study | 84.4 (81.7 to 87.1) |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ibuprofen (Safety Population) | — | 6/736 (0.8%) | 76/736 (10.3%) |
| Event | Ibuprofen (Safety Population) |
|---|---|
| Coronary artery occlusionCardiac disorders | 1/736 |
| Atypical pneumoniaInfections and infestations | 1/736 |
| CellulitisInfections and infestations | 1/736 |
| PneumoniaInfections and infestations | 1/736 |
| Joint dislocationInjury, poisoning and procedural complications | 1/736 |
| NephrolithiasisRenal and urinary disorders | 1/736 |
| Event | Ibuprofen (Safety Population) |
|---|---|
| NasopharyngitisInfections and infestations | 8/736 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 4/736 |
| DizzinessNervous system disorders | 4/736 |
| ConstipationGastrointestinal disorders | 3/736 |
| NauseaGastrointestinal disorders | 3/736 |
| InfluenzaInfections and infestations | 3/736 |
| LacerationInjury, poisoning and procedural complications | 3/736 |
| HeadacheNervous system disorders | 3/736 |
| Abdominal discomfortGastrointestinal disorders | 2/736 |
| DiarrhoeaGastrointestinal disorders | 2/736 |
All participants who purchased at least 1 carton of study medication.
| Age, Continuous(Years) | Ibuprofen |
|---|---|
| Mean | 53.5 ± 13.7 |
| Sex: Female, Male(Participants) | Ibuprofen |
|---|---|
| Female | 412 |
| Male | 326 |
The record gives a start of Nov 2014, a primary completion of May 2015 and a completion of May 2015. It does not say whether these dates are actual or estimated.
Results were first posted in May 2016, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ibuprofen